0001). Topline data were announced from a phase 3 trial evaluating ropeginterferon alfa-2b-njft (P1101), a monopegylated, long-acting interferon, in patients with essential thrombocythemia (ET).

Polycythemia vera and essential thrombocythemia are the most common chronic myeloproliferative neoplasms; their molecular basis has been appreciated only recently and is briefly discussed in this ...

P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET. Among patients with essential thrombocythemia ...